Summary

In a first-of-its-kind clinical trial, U.S. researchers found that people with agitation and dementia in late life who took a special medical formulation of two active ingredients found in marijuana—THC and CBD—had significantly less agitation than people who received a placebo. The primary findings of the multicenter, randomized, double-blind, placebo-controlled Phase II study were presented July 14, 2026, at the Alzheimer's Association International Conference in London by Jacobo Mintzer, MD, of the Medical University of South Carolina, and Georgetown University's Brigid Reynolds, MSN, APRN, ANP-BC.

AI summaries can be wrong sometimes—always verify important details using the source article.